Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease is characterized by amyloid-beta plaques, neurofibrillary tangles, gliosis, and neuronal loss. Solanezumab, a humanized monoclonal antibody, preferentially binds soluble forms of amyloid and in preclinical studies promoted its clearance from the brain. METHODS: In two phase 3, double-blind trials (EXPEDITION 1 and EXPEDITION 2), we randomly assigned 1012 and 1040 patients, respectively, with mild-to-moderate Alzheimer's disease to receive placebo or solanezumab (administered intravenously at a dose of 400 mg) every 4 weeks for 18 months. The primary outcomes were the changes from baseline to week 80 in scores on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog11; range, 0 to 70, with higher scores indicating greater cognitive impairment) and the Alzheimer's Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL; range, 0 to 78, with lower scores indicating worse functioning). After analysis of data from EXPEDITION 1, the primary outcome for EXPEDITION 2 was revised to the change in scores on the 14-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog14; range, 0 to 90, with higher scores indicating greater impairment), in patients with mild Alzheimer's disease. RESULTS: Neither study showed significant improvement in the primary outcomes. The modeled difference between groups (solanezumab group minus placebo group) in the change from baseline was -0.8 points for the ADAS-cog11 score (95% confidence interval [CI], -2.1 to 0.5; P=0.24) and -0.4 points for the ADCS-ADL score (95% CI, -2.3 to 1.4; P=0.64) in EXPEDITION 1 and -1.3 points (95% CI, -2.5 to 0.3; P=0.06) and 1.6 points (95% CI, -0.2 to 3.3; P=0.08), respectively, in EXPEDITION 2. Between-group differences in the changes in the ADAS-cog14 score were -1.7 points in patients with mild Alzheimer's disease (95% CI, -3.5 to 0.1; P=0.06) and -1.5 in patients with moderate Alzheimer's disease (95% CI, -4.1 to 1.1; P=0.26). In the combined safety data set, the incidence of amyloid-related imaging abnormalities with edema or hemorrhage was 0.9% with solanezumab and 0.4% with placebo for edema (P=0.27) and 4.9% and 5.6%, respectively, for hemorrhage (P=0.49). CONCLUSIONS: Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability. (Funded by Eli Lilly; EXPEDITION 1 and 2 ClinicalTrials.gov numbers, NCT00905372 and NCT00904683.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Florbetapir PET analysis did not show a reduction in brain amyloid deposits with solanezumab [45, 46].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [45]
In the citing paper
“bapineuzumab and solanezumab showed no cognitive improvement in Phase 3 trials [46,47]”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [46]
In the citing paper
“Clinical trials often fail to deliver benefits.”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [46]
In the citing paper
“and a similar proportion has normal amyloid PET or CSF Aβ42 studies [53–62].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [57]
In the citing paper
“While recent clinical trials of anti‐amyloid therapies, such as donanemab and lecanemab, 2 , 3 have shown promising results, the failures of earlier treatments like solanezumab and bapineuzumab indicate that targeting a single AD‐specific pathological process is insufficient to mitigate cognitive decline. 4 , 5 , 6”
From White matter hyperintensity modulates the amyloid‐tau‐cognition association and anti‐amyloid treatment efficacy in asymptomatic older adults (2025) · cites this paper as [6]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Sheikh (1986) · doi:10.1300/j018v05n01_09 · Cited by 7,236
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Assessing Quality of Life in Older Adults With Cognitive Impairment
Logsdon, R. G., Gibbons, L. E., McCurry, S. M., & Teri, L. (2002) · Psychosomatic Medicine · doi:10.1097/00006842-200205000-00016 · Cited by 1,381
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Self-citationAn Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease
Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00005 · Cited by 1,194
Self-citationO’Bryant, S. E. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1091 · Cited by 884
Research works printed but not linked: 2
- Wimo A, Wetterholm AL, Mastey V, Winbald B. Evaluations of resource utilization and caregiver time in anti-dementia drug trials- a quantitative battery. In: Wimo A, Jonsson B, Karlsson G, Winbald B, eds. The health economics of dementia. London: John Wiley, 1998:465-99.
- Kind P. 1996. The EuroQol instrument: an index of health-related quality of life. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996:191-201.
Cited by
Items 701–800 of 1,006
Folate/Vitamin B Alleviates Hyperhomocysteinemia-Induced Alzheimer-Like Pathologies in Rat Retina
Guo, J., Ni, S.-Z., Li, Q., Wang, J., & Yang, Y. (2018) · Neuroscience Bulletin · doi:10.1007/s12264-018-0293-8 · Cited by 31
Transthyretin Mimetics as Anti‐β‐Amyloid Agents: A Comparison of Peptide and Protein Approaches
Pate, K. M., Kim, B. J., Shusta, E. V., & Murphy, R. M. (2018) · ChemMedChem · doi:10.1002/cmdc.201800031 · Cited by 30
Kennedy, R., Cutter, G., Fowler, M. E., & Schneider, L. S. S. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.4080 · Cited by 31
Immunotherapy Targeting Neurodegenerative Proteinopathies: α-Synucleinopathies and Tauopathies
Shin, J. H., Kim, H., & Jeon, B. (2019) · Journal of Movement Disorders · doi:10.14802/jmd.19057 · Cited by 32
Influence of Comorbidity of Cerebrovascular Disease and Amyloid-β on Alzheimer’s Disease
Yassi, N., Hilal, S., Xia, Y., Lim, Y. Y., Watson, R., Kuijf, H. J., Fowler, C. J., Yates, P. A., Maruff, P. T., Martins, R. N., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-191028 · Cited by 32
Based on molecular structures: Amyloid-β generation, clearance, toxicity and therapeutic strategies
Yang, H., Li, J., Li, X., Ma, L., Hou, M., Zhou, H., & Zhou, R. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.927530 · Cited by 34
Lenox‐Smith, A., Reed, C. C., Lebrec, J., Belger, M. A., & Jones, R. W. (2016) · BMC Geriatrics · doi:10.1186/s12877-016-0371-6 · Cited by 34
Innate immunity in Alzheimer’s disease: the relevance of animal models?
Franco Bocanegra, D. K., Nicoll, J. A. R., & Boche, D. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-017-1729-4 · Cited by 30
“Other clinical trials of passive immunisation using humanized anti-amyloid antibodies bapineuzumab (Salloway et al. 2014) or solanezumab (Doody et al. 2014) have demonstrated no clear effect in improving cognitive function or slowing rate of decline in participants with established AD.”
BackgroundOng, S. S. Y., Proia, A. D., Whitson, H. E., Farsiu, S., Doraiswamy, P. M., & Lad, E. M. (2018) · Journal of Neurology · doi:10.1007/s00415-018-9028-z · Cited by 33
Fluid Biomarkers in Clinical Trials of Alzheimer’s Disease Therapeutics
Ritter, A. R., & Cummings, J. L. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00186 · Cited by 34
Rockwood, K., Howlett, S. E., Hoffman, D., Schindler, R., & Mitnitski, A. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.02.005 · Cited by 29
“In contrast, ADAS-Cog deterioration would have been fully captured by the DAD.”
MethodInfluentialThe role of PI3K/AKT pathway and its therapeutic possibility in Alzheimer's disease
Yu, H.-J., & Koh, S. (2017) · Hanyang Medical Reviews · doi:10.7599/hmr.2017.37.1.18 · Cited by 35
Brain arterial dilatation and the risk of Alzheimer's disease
Gutierrez, J., Guzmán, V., Khasiyev, F., Manly, J. J., Schupf, N., Andrews, H., Mayeux, R. P., & Brickman, A. M. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.12.018 · Cited by 32
“The prevailing hypothesis of Alzheimer’s disease (AD) pathogenesis is that amyloid deposition initiates a cascade of biological events that lead to dementia and that minimizing amyloid deposition or removing amyloid may prevent, slow, or arrest AD [1,2].”
BackgroundTian, J., Shi, J., Wei, M., Ni, J., Fang, Z., Gao, J., Wang, H., Yao, H., Zhang, J., Li, J., et al. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.03.001 · Cited by 31
Self-citationChen, G., Yang, K. Y., Du, W., Hu, X., & Han, Y. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190501 · Cited by 30
The proteinopenia hypothesis: Loss of Aβ42 and the onset of Alzheimer’s Disease
Espay, A. J., Herrup, K., Kepp, K. P., & Daly, T. P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102112 · Cited by 36
“…A β but the marked increase they induced in soluble A β 42 levels (lecanemab increases CSF levels of A β 42 by 288 pg/ml (van Dyck et al., 2023) whereas other monoclonal antibodies do so to a lower extent; solanezumab, for instance, increases such levels by only 37 pg/ml (Doody et al., 2014)).”
BackgroundAutophagy is involved in oral rAAV/Aβ vaccine-induced Aβ clearance in APP/PS1 transgenic mice
Wang, H.-C., Zhang, T., Kuerban, B., Jin, Y.-L., Le, W., Hara, H., Fan, D.-S., Wang, Y., Tabira, T., & Chui, D.-H. (2015) · Neuroscience Bulletin · doi:10.1007/s12264-015-1546-4 · Cited by 30
Morrone, C. D., Liu, M., Black, S. E., & McLaurin, J. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00064 · Cited by 26
Froestl, W., Pfeifer, A., & Muhs, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121729 · Cited by 33
Dantas, J. M., Mutarelli², A. M., Navalha, D. D. P., Dagostin, C. S., Romeiro, P. H. C. L., Felix, N. S., Nogueira, A., Batista, S., Teixeira, L., & Caramelli, P. (2023) · Neurological Sciences · doi:10.1007/s10072-023-07194-w · Cited by 32
Gong, B., Zhang, W., Cong, W., Gu, Y., Ji, W., Yin, T., Zhou, H., Hu, H., Zhuang, J., Luo, Y., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400149 · Cited by 44
Increases in amyloid-β42 slow cognitive and clinical decline in Alzheimer’s disease trials
Abanto, J. T., Dwivedi, A. K., Imbimbo, B. P., & Espay, A. J. (2024) · Brain · doi:10.1093/brain/awae216 · Cited by 39
Tonegawa‐Kuji, R., Hou, Y., Hu, B., Lorincz‐Comi, N. J., Pieper, A. A., Tousi, B., Leverenz, J. B., & Cheng, F. (2025) · PLoS Medicine · doi:10.1371/journal.pmed.1004568 · Cited by 36
“Two studies tested gantenerumab [13], one study tested donanemab [4], one study tested lecanemab [2], two studies tested aducanumab [3], three studies tested solanezumab [16,17], and four studies tested bapineuzumab [32,33].”
Alzheimer disease: Amyloid peptide controversies and challenges of anti-Aβ immunotherapy
Almohmadi, N. H., Al-Kuraishy, H. M., Albuhadily, A. K., Al-Gareeb, A. I., Abdelaziz, A. M., Alexiou, A. T., Papadakis, M., & Batiha, G. E. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103639 · Cited by 30
“65,66 Although bapineuzumab reduced CSF cerebral amyloid plaques and phosphorylated tau protein levels, hallmarks of AD neuropathology, it did not improve cognitive function.”
Optimization of image reconstruction conditions with phantoms for brain FDG and amyloid PET imaging
Akamatsu, G., Ikari, Y., Nishio, T., Nishida, H., Ohnishi, A., Aita, K., Sasaki, M., Sasaki, M., & Senda, M. (2015) · Annals of Nuclear Medicine · doi:10.1007/s12149-015-1024-0 · Cited by 34
A Theoretical Analysis of the Synergy of Amyloid and Tau in Alzheimer’s Disease
Han, P., & Shi, J. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151206 · Cited by 33
Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies
Golde, T. E. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13583 · Cited by 29
Izumi, H., Shinoda, Y., Saito, T., Saido, T. C., Sato, K., Yabuki, Y., Matsumoto, Y., Kanemitsu, Y., Tomioka, Y., Abolhassani, N., et al. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.02.031 · Cited by 29
Zhao, L., Initiative, A. D. N., Luo, Y., Lew, D., Liu, W., Au, L. W. C., Mok, V., & Shi, L. (2019) · Aging · doi:10.18632/aging.102184 · Cited by 33
Spatially Distributed Amyloid-β Reduces Glucose Metabolism in Mild Cognitive Impairment
Carbonell, F., Zijdenbos, A. P., Bedell, B. J., & Initiative, F. T. A. D. N. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190560 · Cited by 28
“In fact, stud619 ies of potential therapeutic agents designed to reduce 620 A have employed composite ROI scores as an out621 come measure [39, 40].”
MethodXiao, Q., Ye, T., Wang, X., Han, L., Wang, T.-X., Qi, D., Cheng, X., & Wang, S. (2021) · Experimental Gerontology · doi:10.1016/j.exger.2021.111336 · Cited by 29
Next-generation antibody-based therapies in neurology
Ruck, T., Nimmerjahn, F., Wiendl, H., & Lünemann, J. D. (2021) · Brain · doi:10.1093/brain/awab465 · Cited by 29
Wadood, A., Shareef, A., Rehman, A. U., Muhammad, S., Khurshid, B., Khan, R. S., Shams, S., & Afridi, S. G. (2021) · ACS Omega · doi:10.1021/acsomega.1c04764 · Cited by 28
Hu, W., Wang, Z., Zhang, H., Mahaman, Y. A. R., Huang, F., Meng, D., Zhou, Y., Wang, S., Jiang, N., Xiong, J., et al. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01204-z · Cited by 30
Han, Y., Chen, L., Liu, J., Chen, J., Wang, C., Guo, Y., Yu, X., Zhang, C., Chu, H., & Ma, H. (2022) · Molecules · doi:10.3390/molecules27134160 · Cited by 29
“, solanezumab, have failed in AD drug experimental studies [8].”
BackgroundSalemme, S., Ancidoni, A., Locuratolo, N., Piscopo, P., Lacorte, E., Canevelli, M., & Vanacore, N. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2284305 · Cited by 28
Epelbaum, S., Youssef, I., Lacor, P. N., Chaurand, P., Duplus, E., Brugg, B., Duyckaerts, C. J., & Delatour, B. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.03.005 · Cited by 44
Piechotta, A., Parthier, C., Kleinschmidt, M., Gnoth, K., Pillot, T., Lues, I., Demuth, H., Schilling, S., Rahfeld, J., & Stubbs, M. T. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.777839 · Cited by 29
“clinical trials with anti-A antibodies have by and large been disappointing (2, 16, 17).”
BackgroundA Toxic Conformer of Aβ42 with a Turn at 22–23 is a Novel Therapeutic Target for Alzheimer’s Disease
Izuo, N., Kasahara, C., Murakami, K., Kume, T., Maeda, M., Irie, K., Yokote, K., & Shimizu, T. (2017) · Scientific Reports · doi:10.1038/s41598-017-11671-6 · Cited by 31
KDS2010: A Potent Highly Selective and Reversible MAO-B Inhibitor for Alzheimer’s Disease
Mamun, A. A., & Uddin, M. S. (2020) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207323666200117103144 · Cited by 27
Campbell, J., Lavoie, L., Farraia, M., Huelin, R., Zhang, Q., & Monfared, A. A. T. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00676-9 · Cited by 35
Panza, F., Dibello, V., Sardone, R., Zupo, R., Castellana, F., Leccisotti, I., Moretti, M. C., Altamura, M., Bellomo, A., Daniele, A., et al. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2463963 · Cited by 30
“At this regard, solanezumab produced an increase in total CSF Aβ 1–42 levels in both ADAD and sporadic AD patients related to the bound fraction of Aβ 1–42 , while the free Aβ 1–42 fraction could be unchanged or reduced due to antibody binding [36].”
Lenox‐Smith, A., Reed, C. C., Lebrec, J., Belger, M. A., & Jones, R. W. (2018) · BMC Geriatrics · doi:10.1186/s12877-018-0748-9 · Cited by 27
Linking Late Life Depression and Alzheimer’s Disease: Mechanisms and Resilience
Weisenbach, S. L., Kim, J. U., Hammers, D. B., Konopacki, K. L., & Koppelmans, V. (2019) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-019-00180-7 · Cited by 33
Alzheimer’s protection effect of A673T mutation may be driven by lower Aβ oligomer binding affinity
Limegrover, C. S., LeVine, H., Izzo, N. J., Yurko, R., Mozzoni, K., Rehak, C., Sadlek, K., Safferstein, H., & Catalano, S. M. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15212 · Cited by 24
“Monoclonal antibodies with high affinity for monomer, such as solanezumab, have not been clinically efficacious (Doody et al., 2014; Honig et al., 2018).”
BackgroundReiss, A. B., Montufar, N., DeLeon, J. R., Pinkhasov, A., Gomolin, I. H., Glass, A. D., Arain, H. A., & Stecker, M. M. (2021) · The Neurologist · doi:10.1097/nrl.0000000000000320 · Cited by 28
Ligustrazine Attenuates Hyperhomocysteinemia-induced Alzheimer-like Pathologies in Rats
Zhang, Q., Wang, J., Zhu, L., Jiang, S., Liu, J., Wang, L., & Qin, X. (2021) · Current Medical Science · doi:10.1007/s11596-021-2379-1 · Cited by 29
Martins, A. F., Oliveira, A. C., Morfin, J., Laurents, D. V., Tóth, É., & Geraldes, C. F. G. C. (2015) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-015-1316-9 · Cited by 28
Chen, J., Zhang, T., Jiao, S., Zhou, X., Zhong, J., Wang, Y., Liu, J., Deng, J., Wang, S., & Xu, Z. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161191 · Cited by 29
A short perspective on the long road to effective treatments for Alzheimer's disease
Reynolds, D. S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14581 · Cited by 29
Modeling Alzheimer’s disease using human cell derived brain organoids and 3D models
Fernandes, S., Revanna, J. S., Pratt, J. M., Hayes, N., Marchetto, M. C., & Gage, F. H. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1434945 · Cited by 45
“Several potential AD drugs which showed promise during animal trials failed during phase III clinical trials (Doody et al., 2014; Salloway et al., 2014).”
BackgroundKuo, Y., & Rajesh, R. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1621750 · Cited by 27
“They elevated Aβ38 activity at the expense of Aβ42, and natural products exhibited a noteworthy reduction in Aβ42 relative to Aβ40 in a cell-based assay.”
BackgroundInfluentialAmyloid Beta Hypothesis in Alzheimer's Disease: Major Culprits and Recent Therapeutic Strategies
Dileep, K. V., & Chandra, R. (2019) · Current Drug Targets · doi:10.2174/1389450120666190806153206 · Cited by 27
Emerging Developments in Targeting Proteotoxicity in Neurodegenerative Diseases
McAlary, L., Plotkin, S. S., & Cashman, N. R. (2019) · CNS Drugs · doi:10.1007/s40263-019-00657-9 · Cited by 28
Panayiotou, E., Fella, E., Andreou, S., Papacharalambous, R., Gerasimou, P., Costeas, P., Angeli, S., Kousiappa, I., Papacostas, S., & Kyriakides, T. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225417 · Cited by 30
Smedinga, M., Darweesh, S. K. L., Bloem, B. R., Post, B., & Richard, E. (2020) · Journal of Neurology · doi:10.1007/s00415-020-10162-5 · Cited by 29
Brain metastasis models: What should we aim to achieve better treatments?
Masmudi‐Martín, M., Zhu, L., Sánchez‐Navarro, M., Priego, N., Casanova-Acebes, M., Ruiz‐Rodado, V., Giralt, E., & Valiente, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.002 · Cited by 27
Grill, J. D., Raman, R., Ernstrom, K. B., Aisen, P. S. S., Dowsett, S. A., Chen, Y.-F., Liu‐Seifert, H., Hake, A. M., Miller, D. S., Doody, R. S., et al. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0122-5 · Cited by 32
Self-citationFunction and clinical meaningfulness of treatments for mild Alzheimer's disease
Siemers, E., Holdridge, K. C., Sundell, K. L., & Liu‐Seifert, H. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.02.006 · Cited by 28
Self-citationDavis, P. R., Giannini, G., Rudolph, K., Calloway, N. T., Royer, C. M., Beckett, T. L., Murphy, M. P., Bresch, F., Pagani, D., Platt, T. L., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.09.007 · Cited by 30
Cleavage of potassium channel Kv2.1 by BACE2 reduces neuronal apoptosis
Liu, F., Zhang, Y., Liang, Z., Sun, Q., Liu, H., Zhao, J., Xu, J., Zheng, J., Yun, Y., Yu, X., et al. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0060-2 · Cited by 27
Self-citationA guide to using functional magnetic resonance imaging to study Alzheimer's disease in animal models
Asaad, M., & Lee, J. H. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.031724 · Cited by 27
“This disconnect could explain why some treatments that improve cognition in animals fail to do so in human patients (Doody et al., 2014; Holmes et al., 2008; Salloway et al., 2014; Vellas et al., 2013).”
Neuro-Immuno-Gene- and Genome-Editing-Therapy for Alzheimer’s Disease: Are We There Yet?
Raikwar, S. P., Thangavel, R., Dubova, I., Ahmed, M. E., Selvakumar, G. P., Kempuraj, D., Zaheer, S. A., Iyer, S. S., & Zaheer, A. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180422 · Cited by 32
Clausznitzer, D., Pichardo‐Almarza, C., Relo, A. L., van Bergeijk, J., van der Kam, E. L., Laplanche, L., Benson, N., & Nijsen, M. (2018) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12351 · Cited by 28
Alzheimer's Disease: Many Failed Trials, So Where Do We Go from Here?
Reiss, A. B., Glass, A. D., Wısnıewskı, T., Wolozin, B. L., Gomolin, I. H., Pinkhasov, A., Leon, J. D., & Stecker, M. M. (2020) · Journal of Investigative Medicine · doi:10.1136/jim-2020-001297 · Cited by 27
Takamatsu, Y., Ho, G. J., Koike, W., Sugama, S., Takenouchi, T., Waragai, M., Wei, J., Sekiyama, K., & Hashimoto, M. (2017) · npj Parkinson s Disease · doi:10.1038/s41531-016-0001-1 · Cited by 29
“Although two independent phase III clinical trials of solanezumab failed to meet their endpoints, pooled data from these two studies demonstrated a statistically significant slowing of cognitive decline in mild AD but not moderate AD.(14) A confirmation trial of solanezumab is currently underway to determine if the ef…”
BackgroundInfluentialKnowledge gaps in Alzheimer's disease immune biomarker research
Morgan, D., & Mielke, M. M. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12342 · Cited by 27
Soloperto, A., Quaglio, D., Baiocco, P., Romeo, I., Mori, M., Ardini, M., Presutti, C., Sannino, I., Ghirga, S., Iazzetti, A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-09016-z · Cited by 29
Siemers, E., Hitchcock, J., Sundell, K. L., Dean, R. A., Jerecic, J., Cline, E. N., Iverson, K., Moore, J. A., Edgar, C. J., Manber, R., et al. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.93 · Cited by 33
“In addition to reviewing nonclinical data for ACU193, trial designs for other AD treatments including other monoclonal antibodies were evaluated (3, 5, 29-31).”
BackgroundSelf-citationSandberg, A., Berenjeno‐Correa, E., Rodriguez, R. C., Axenhus, M., Weiss, S. S., Batenburg, K. L., Hoozemans, J. J. M., Tjernberg, L. O., & Scheper, W. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01141-1 · Cited by 31
“Previously tested anti-Aβ mAbs, such as solanezumab and bapineuzumab, had high intrinsic affinities for Aβ peptides in general (both have KD values in the low nM range [80]); therefore, they suffered from extensive target distraction and proved to be ineffective at reducing brain amyloid or affecting clinical outcomes…”
BackgroundPreventing Alzheimer's disease by means of natural selection
Demetrius, L., & Driver, J. A. (2015) · Journal of The Royal Society Interface · doi:10.1098/rsif.2014.0919 · Cited by 25
Zhang, J., Liu, Z., Zhang, H., Yang, C., He, L., Li, X., Chen, K., & Zhang, Z. (2016) · Scientific Reports · doi:10.1038/srep28982 · Cited by 28
Alzheimer's disease and other dementias: update on research
Schneider, L. S. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30356-8 · Cited by 25
Hanfelt, J., Peng, L., Goldstein, F. C., & Lah, J. J. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.05.025 · Cited by 29
“Unfortunately, to date, none of these trials has achieved their primary outcome measures (Cummings et al., 2017; Doody et al., 2014; Salloway et al., 2014).”
Boutajangout, A., Lindberg, H., Awwad, A., Paul, A., Baitalmal, R., Almokyad, I. K., Höidén‐Guthenberg, I., Gunneriusson, E., Frejd, F. Y., Härd, T., et al. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00064 · Cited by 26
“However, translation to safe and efficacious therapies for humans has been challenging as AD clinical trials have failed to show sufficient clinical benefits (Doody et al., 2014; Salloway et al., 2014; Herline et al., 2018b).”
BackgroundZhang, S., Zhang, J.-X., Wei, D., An, H., Liu, W., Lai, Y.-H., Yang, T., Shao, W., Huang, Y., Wang, L., et al. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109682 · Cited by 31
Cao, K., Dong, Y., Xiang, J., Xu, Y., Li, Y., Song, H., Yu, W., Qi, X., & Guan, Z.-Z. (2019) · Aging · doi:10.18632/aging.102713 · Cited by 27
Kalium Nitrat (KNO3): Karakteristik Senyawa dan Transpor IonPreprint
Nurfadilah, K. K., & Zainul, R. (2019) · INA-Rxiv (OSF Preprints) · doi:10.31227/osf.io/dr8ef · Cited by 26
Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease
Sumner, I. L., Edwards, R. A., Asuni, A. A., & Teeling, J. L. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00254 · Cited by 24
“The phase 3 trials of this drug (EXPEDITION 1 and EXPEDITION 2) showed no significant improvement in primary outcomes, despite only 0.9% ARIAs with Solanezumab and 0.4% with placebo (Doody et al., 2014).”
BackgroundInfluentialFyn Kinase in Alzheimer’s Disease: Unraveling Molecular Mechanisms and Therapeutic Implications
Meur, S., & Karati, D. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04286-2 · Cited by 28
Immunotherapy for Parkinson’s Disease and Alzheimer’s Disease: A Promising Disease-Modifying Therapy
Mahboob, A., Ali, H., Naimi, A. J. A., Yousef, M., Rob, M., Al-Muhannadi, N. A., Senevirathne, D. K. L., & Châari, A. (2024) · Cells · doi:10.3390/cells13181527 · Cited by 31
“Ongoing research aims to optimize dosing and patient selection to enhance gantenerumab’s therapeutic potential [44].”
BackgroundOligomeric tau-targeted immunotherapy in Tg4510 mice
Schroeder, S. K., Joly‐Amado, A., Soliman, A. S., Sengupta, U., Kayed, R., Gordon, M. N., & Morgan, D. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0274-6 · Cited by 25
“One of the first approaches to reducing brain Aβ was the use of immunotherapy [5, 6] and this approach has advanced to phase 3 clinical testing [7, 8].”
Chen, Y., Wei, G., Zhao, J., Nussinov, R., & Ma, B. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00364 · Cited by 24
Petersen, K. K., Lipton, R. B., Grober, E. H., Davatzikos, C. A., Sperling, R. A., & Ezzati, A. (2022) · Neurology · doi:10.1212/wnl.0000000000200553 · Cited by 28
“Early diagnosis and intervention to reduce Aβ accumulation is considered a potential approach to modify disease course and has been the focus of many of the recent clinical trials involving cognitively normal (CN) participants.(3,4) Most of these trials require biomarker confirmation of amyloid positivity as a criteri…”
BackgroundRole of autophagy in the pathogenesis of Alzheimer disease
Kızılarslanoğlu, M. C., & Ülger, Z. (2015) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1407-75 · Cited by 24
Hempel, P., Heinig, B., Jerosch, C., Decius, I., Karczewski, P., Kassner, U., Kunze, R., Steinhagen‐Thiessen, E., & Bimmler, M. (2016) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12415 · Cited by 24
Statistical properties of continuous composite scales and implications for drug development
Liu-Seifert, H., Andersen, S., Case, M., Sparks, J., Holdridge, K. C., Wessels, A. M., Hendrix, S., Aisen, P., & Siemers, E. (2017) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2017.1315819 · Cited by 24
“…studies The solanezumab EXPEDITION (NCT00905372) and EXPEDITION2 (NCT00904683) studies were Phase 3, placebo-controlled studies investigating solanezumab treatment in patients withmild-to-moderate AD (Mini Mental State Examination [MMSE] 16 through 26) over 80 weeks (Doody et al., 2014).”
BackgroundSelf-citationMin, K. C., Dockendorf, M. F., Palcza, J. S., Tseng, J., Ma, L., Stone, J. A., Kleijn, H. J., Hodsman, P., Masuo, K., Tanen, M., et al. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1258 · Cited by 26
Grasping at straws: the failure of solanezumab to modify mild Alzheimer’s disease
Doggrell, S. A. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1543397 · Cited by 26
“In these studies, the ability of solanezumab to lower the cerebrospinal fluid levels of Aβ peptide was not associated with a difference in the amyloid imagining in the brains analyzed [11].”
BackgroundStewart, T., Initiative, A. F. T. A. D. N., Shi, M. Y., Mehrotra, A., Aro, P., Soltys, D., Kerr, K. F., Zabetian, C. P., Peskind, E. R., Taylor, P., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190069 · Cited by 27
Abdullah, L. I., Crawford, F., Tsolaki, M., Börjesson‐Hanson, A., Rikkert, M. G. M. O., Pasquier, F., Wallin, A., Kennelly, S., Ait‐Ghezala, G., Paris, D., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00149 · Cited by 26
“These findings are also consistent with the results of several other experimental AD treatments where only very early stage AD subjects demonstrated benefit, such as Solanezumab (7, 10, 30), aducanumab (8), and LipiDiDiet trials (9).”
ResultAmyloid β: Walking on the dark side of the moon
Fedele, E., Rivera, D., Marengo, B., Pronzato, M. A., & Ricciarelli, R. (2015) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2015.09.001 · Cited by 27
The Positive Effects of Viewing Gardens for Persons with Dementia
Goto, S., Shen, X., Sun, M., Hamano, Y., & Herrup, K. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170510 · Cited by 36
Ahmad, S. S., Khan, S. M., Kamal, M. A., & Wasi, U. (2019) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527318666191011145941 · Cited by 26
Wang, G., Kennedy, R., Goldberg, T. E., Fowler, M. E., Cutter, G., & Schneider, L. S. S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228064 · Cited by 27
“Similar to previous trials [1, 3], we first estimated the mean (SD) of the 2-year change from baseline, then under the assumption of equal variance among the treatment groups, we estimate the sample size for a given treatment effect using two-sample t-tests and equal randomization ratio.”
BackgroundMethodInfluentialPreventing Alzheimer's disease within reach by 2025: Targeted‐risk‐AD‐prevention (TRAP) strategy
Vitali, F., Branigan, G. L., & Brinton, R. D. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12190 · Cited by 35
Gao, D., Li, P., Gao, F., Feng, Y., Li, X., Li, D., Li, Y., & Xiao, Y. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/9466166 · Cited by 23
“Therefore, most clinical trials of disease-modifying treatment (DMT) drugs focus on the primary targets of Aβ and tau protein for AD prevention or therapy, such as solanezumab [4], avagacestat [5], and idalopirdine [6].”
BackgroundRetractedTherapeutic anti‐amyloid β antibodies cause neuronal disturbances
Adhikari, U. K., Khan, R. H., Mikhael, M., Balez, R., David, M. A., Mahns, D. A., Hardy, J., & Tayebi, M. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12833 · Cited by 28
Identification of Alzheimer’s Disease by Imaging: A Comprehensive Review
Prasath, T. A., & Sumathi, V. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20021273 · Cited by 32
“The most plausible reason for these failures is that the administration of the drug at a point in the disease’s neuropathology is considered to be late [1].”
BackgroundPrevention Trials in Alzheimer’s Disease: Current Status and Future Perspectives
Wang, J., Tan, L., & Yu, J.-T. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150826 · Cited by 23
Metadata
- Authors
- Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., & Mohs, R.
- Affiliations
- Baylor College of Medicine (US)
- University of California San Diego (US)
- Indiana University (US)
- The University of Tokyo (JP)
- Centre Hospitalier Universitaire de Toulouse (FR)
- University of Pennsylvania (US)
- University of Rochester Medicine (US)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-01-23
- Volume
- 370
- Issue
- 4
- Pages
- 311-321
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2015484447
- Cited by
- 1,668
- References
- 28
- Citations by year
- 2026: 63 · 2025: 84 · 2024: 110 · 2023: 116 · 2022: 101 · 2021: 103 · 2020: 154 · 2019: 145 · 2018: 155 · 2017: 163 · 2016: 183 · 2015: 178 · 2014: 111
- FWCI
- 140.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- solanezumab, Alzheimer's disease, amyloid-beta, anti-amyloid monoclonal antibodies, cognitive impairment, activities of daily living, mild to moderate Alzheimer's disease, placebo response
- MeSH terms
- Activities of Daily Living, Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Cognition, Double-Blind Method, Female, Humans, Male, Neuropsychological Tests, Severity of Illness Index, Biomarkers, Amyloid beta-Peptides, tau Proteins, Treatment Failure, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.